---
title: "Lilly's orforglipron calcium tablet approved for marketing in China — DecisionGateway"
description: "Lilly's orforglipron calcium tablet approved for marketing in China"
canonical_url: "https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a"
meta:
  "og:description": "Lilly's orforglipron calcium tablet approved for marketing in China"
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "DecisionGateway — a cluster of glowing dots pulling toward one bright center on dark"
  "og:image:height": "630"
  "og:image:width": "1200"
  "og:title": "Lilly's orforglipron calcium tablet approved for marketing in China — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

**Event**/Regulatory approval

**Completed**

# **Lilly's orforglipron calcium tablet approved for marketing in China**

**Trajectories**

Explore probable futures of this record — up to three arcs with a direction, a probability and a horizon.

## **Actors and targets**

[礼来participant](https://dgw.tmarket.io/actors/01a20495-cd8f-718d-8502-11aefd9e9784)

[**礼来 dossier **](https://dgw.tmarket.io/actors/01a20495-cd8f-718d-8502-11aefd9e9784)

## **Source**

> 礼来奥氟格列隆钙片获批上市，为国内首个口服GLP-1类减重药物。

*clsvip · Telegram [ Open post](https://t.me/clsvip/37503)*

## **Related events**

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a#webpage","@type":"WebPage","description":"Lilly's orforglipron calcium tablet approved for marketing in China","name":"Lilly's orforglipron calcium tablet approved for marketing in China — DecisionGateway","url":"https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a","breadcrumb":{"@id":"https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/events/01a20495-cdb9-7306-a77b-377149e0e58a#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Feed","item":"https://dgw.tmarket.io/feed","position":2},{"@type":"ListItem","name":"Lilly's orforglipron calcium tablet approved for marketing in China","position":3}]}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
